MARKET

IMRA

IMRA

Imara Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

14.04
-0.01
-0.07%
After Hours: 14.03 -0.01 -0.07% 17:56 01/22 EST
OPEN
14.04
PREV CLOSE
14.05
HIGH
14.16
LOW
13.80
VOLUME
85.00K
TURNOVER
--
52 WEEK HIGH
62.71
52 WEEK LOW
12.90
MARKET CAP
244.40M
P/E (TTM)
-2.4438
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Imara Announces the Appointment of Kenneth Attie, M.D. as Chief Medical Officer
Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced the appointment of Kenneth...
GlobeNewswire · 4d ago
Imara Announces the Appointment of Kenneth Attie, M.D. as Chief Medical Officer
Brings 30 years of medical research experience within the biopharmaceutical industry, including Acceleron Pharma and GenentechBOSTON, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to devel...
GlobeNewswire · 4d ago
Imara declined yesterday as its sickle cell treatment appears to be not at par with its peers
Imara (IMRA) closed in red, down 38% yesterday as investors apparently saw the company's sickle cell data lacked benefit when compared to its peers.Data showed that IMR-687 had no meaningful impact on
Seekingalpha · 01/07 12:36
Imara Analyst Says Buy The Weakness Ahead Of Multiple 2021 Data Readouts
Imara Inc (NASDAQ: IMRA) shares took a thrashing Wednesday following the release of mid-stage results of its IMR-687 in sickle cell disease.Underwhelming Data: IMR-687 failed to close part of the gap from the 1.7% absolute increase in fetal hemoglobin, or ...
Benzinga · 01/06 22:21
Mid-Afternoon Market Update: Dow Surges Over 600 Points; Imara Shares Plunge
Toward the end of trading Wednesday, the Dow traded up 2.02% to 31,005.69 while the NASDAQ rose 0.61% to 12,897.65. The S&P also rose, gaining 1.46% to 3,781.21.
Benzinga · 01/06 19:34
CLSK, ISR, SYN and BBI among midday movers
Gainers: Isoray (ISR) +187%.The9 (NCTY) +48%.9 Meters Biopharma (NMTR) +40%.AIkido Pharma (AIKI) +40%.Guardion Health Sciences (GHSI) +38%.TAT Technologies (TATT) +35%.Orchard Therapeutics (ORTX) +35%.Change Healthcare (CHNG) +31%.CleanSpark (CLSK) +30%.CBAK Energy Technology (CBAT) +28%.Losers: IMARA (IMRA) -35%.Second Sight Medical Products (EYES) -23%.Mexco
Seekingalpha · 01/06 17:47
Mid-Day Market Update: Gold Down Over 2%; Change Healthcare Shares Jump
Midway through trading Wednesday, the Dow traded up 1.63% to 30,886.85 while the NASDAQ rose 0.53% to 12,886.46. The S&P also rose, gaining 1.17% to 3,770.50.
Benzinga · 01/06 17:24
Isoray, Guardion Health Sciences leads healthcare gainers; IMARA, Synthetic Biologics among major losers
Gainers: Isoray (ISR) +181%, Guardion Health Sciences (GHSI) +57%, AIkido Pharma AIKI +57%, Orchard Therapeutics ORTX +41%, Change Healthcare CHNG +31%.Losers: IMARA IMRA -35%, Synthetic Biologics (SYN) -25%, Second Sight Medical Products (EYES) -22%, Atossa Therapeutics ATOS -21%, Brickell Biotech (BBI) -10%.
Seekingalpha · 01/06 16:01
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IMRA. Analyze the recent business situations of Imara Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average IMRA stock price target is 41.33 with a high estimate of 59.00 and a low estimate of 30.00.
EPS
Institutional Holdings
Institutions: 42
Institutional Holdings: 11.23M
% Owned: 64.50%
Shares Outstanding: 17.41M
TypeInstitutionsShares
Increased
8
933.01K
New
6
-25.35K
Decreased
16
614.12K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.07%
Pharmaceuticals & Medical Research
+0.80%
Key Executives
Chairman/Independent Director
David Mott
President/Chief Executive Officer/Director
Rahul Ballal
Chief Financial Officer/Chief Operating Officer/Primary Contact
Michael Gray
Senior Vice President
Lynette Hopkinson
Director
Edward Conner
Independent Director
Mette Agger
Independent Director
David Bonita
Independent Director
Mark Chin
Independent Director
Barbara Dalton
Independent Director
Carl Goldfischer
Independent Director
Sara Nayeem
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About IMRA
Imara, Inc. is a clinical-stage biopharmaceutical company. The Company is developing and commercializing therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. The Company’s product pipeline include IMR-687, which is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease (SCD), and beta-thalassemia. Its IMR-687 is a selective, small molecule inhibitor of phosphodiesterase-9 (PDE9). The Company is conducting a Phase 2a clinical trial of IMR-687 in adult patients with SCD and a Phase 2b clinical trial for the treatment of patients with beta-thalassemia.
More

Webull offers kinds of Imara Inc stock information, including NASDAQ:IMRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMRA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IMRA stock methods without spending real money on the virtual paper trading platform.